I thought I would spread the word....
A new canine NSAID came on the market last March, called galliprant. It apparently is not a COX inhibitor so it works differently than the others.
I was reading the insert: http://www.aratana.com/Galliprant
And I saw that it's a p-glycoprotein substrate which would mean that it shouldn't be used in mdr1 dogs. The mdr1 lab has not tested yet in canines (I contacted the lab and it appears it was tested with the human version and they have not yet tested it for dogs).
So please get the word out if you see friends mentioning this drug on FB, etc., that it shouldn't be used in mdr1 dogs until the VCPL tests it, and, as with HW treatment, dogs should be tested for the mdr1 mutation before using it, particularly if it's a susceptible breed or any type of a mix.
I think it's incredibly IRRESPONSIBLE for this drug to be released without being fully tested.